These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 6894031)
1. Enhanced 6-oxo-PGF1 alpha levels in plasma during hemodialysis. Leithner C; Sinzinger H; Stummvoll HK; Klein K; Silberbauer K; Peskar BA Prostaglandins Med; 1980 Dec; 5(6):425-7. PubMed ID: 6894031 [TBL] [Abstract][Full Text] [Related]
2. Platelet microaggregates and release of endogenous prostacyclin during the initial phase of haemodialysis. Leithner C; Sinzinger H; Silberbauer K; Stummvoll HK Proc Eur Dial Transplant Assoc; 1981; 18():122-5. PubMed ID: 7036146 [TBL] [Abstract][Full Text] [Related]
3. Measurement of 6-oxo-PGF1 alpha in human plasma using gas chromatography-mass spectrometry. Hensby CN; Fitzgerald GA; Friedman LA; Lewis PJ; Dollery CT Prostaglandins; 1979 Nov; 18(5):731-6. PubMed ID: 396578 [TBL] [Abstract][Full Text] [Related]
4. Prostacyclin and thromboxane in chronic uremia: effect of hemodialysis. Ylikorkala O; Huttunen K; Järvi J; Viinikka L Clin Nephrol; 1982 Aug; 18(2):83-7. PubMed ID: 6754193 [TBL] [Abstract][Full Text] [Related]
5. Blood levels of 6-oxo-prostaglandin F 1 alpha during endotoxin-induced hypotension in rabbits. Bult H; Beetens J; Herman AG Eur J Pharmacol; 1980 Apr; 63(1):47-56. PubMed ID: 6991259 [TBL] [Abstract][Full Text] [Related]
6. Stimulation of vascular prostacyclin (PGI2) production by human serum. Ritter JM; Orchard MA; Lewis PJ Biochem Pharmacol; 1982 Oct; 31(19):3047-50. PubMed ID: 6756409 [TBL] [Abstract][Full Text] [Related]
7. In-vitro production of prostaglandin E, F and 6-oxo-prostaglandin F1 alpha by the uterine and ovarian tissues of pseudopregnant rabbits. Satoh K; Kawai Y; Ozaki A; Kinoshita K; Sakamoto S Prostaglandins Leukot Med; 1983 Aug; 11(4):401-14. PubMed ID: 6578520 [TBL] [Abstract][Full Text] [Related]
8. The effect of clinical prostacyclin infusions in advanced arterial disease on platelet function and plasma 6-keto PGF1 alpha levels. Machin SJ; Chamone DA; Defreyn G; Vermylen J Br J Haematol; 1981 Mar; 47(3):413-22. PubMed ID: 7006673 [TBL] [Abstract][Full Text] [Related]
9. Prostanoid synthesis by aortic rings in human blood: selective increase of prostacyclin mediated by a serum factor. Ritter JM Br J Pharmacol; 1984 Oct; 83(2):409-18. PubMed ID: 6386089 [TBL] [Abstract][Full Text] [Related]
10. Increased plasma-6-oxo-PGF1-alpha but normal PGI2 half-life in patients with maxillo-facial tumors. Porteder H; Matejka M; Kment G; Nell A; Sinzinger H Prog Clin Biol Res; 1987; 242():123-9. PubMed ID: 3313409 [TBL] [Abstract][Full Text] [Related]
11. [Plasma level and effects of thromboxane A2 and 6-keto-PGF1 alpha in patients with acute obstructive suppurative cholangitis]. Miao XY Zhonghua Wai Ke Za Zhi; 1990 Apr; 28(4):228-30, 253-4. PubMed ID: 2379443 [TBL] [Abstract][Full Text] [Related]
12. Elimination of prostacyclin (PGI2) and 6-oxo-PGF1 alpha in anaesthetized dogs. Salmon JA; Mullane KM; Dusting GJ; Moncada S; Vane JR J Pharm Pharmacol; 1979 Aug; 31(8):529-32. PubMed ID: 39993 [TBL] [Abstract][Full Text] [Related]
13. Peripheral plasma immunoreactive 6-oxo-prostaglandin F1 alpha and gynaecological tumours. Alam M; Jogee M; MacGregor WG; Dowdell JW; Elder MG; Myatt L Br J Cancer; 1982 Mar; 45(3):384-9. PubMed ID: 6896152 [TBL] [Abstract][Full Text] [Related]
14. Evidence for isosorbide dinitrate (ISDN) promoting effect on prostacyclin release by the lung and prostacyclin implication in ISDN-induced inhibition of platelet aggregation in humans. Rolland PH; Bory M; Leca F; Sainsous J; Gueydon E; Juhan I; Serradimigni A; Cano JP Prostaglandins Leukot Med; 1984 Dec; 16(3):333-46. PubMed ID: 6396656 [TBL] [Abstract][Full Text] [Related]
15. Effects of prostacyclin during cardiopulmonary bypass in men on plasma levels of beta-thromboglobulin, platelet factor 4, thromboxane B2, 6-keto-prostaglandin F1 alpha and heparin. Ditter H; Heinrich D; Matthias FR; Sellmann-Richter R; Wagner WL; Hehrlein FW Thromb Res; 1983 Nov; 32(4):393-408. PubMed ID: 6197766 [TBL] [Abstract][Full Text] [Related]
16. Elevated plasma glycocalicin levels and decreased ristocetin-induced platelet agglutination in hemodialysis patients. Himmelfarb J; Nelson S; McMonagle E; Holbrook D; Benoit SE; Michelson AD; Ault K Am J Kidney Dis; 1998 Jul; 32(1):132-8. PubMed ID: 9669434 [TBL] [Abstract][Full Text] [Related]
17. [Circulating platelet aggregates during haemodialysis]. Silberbauer KF; Wolf A; Stummvoll HK; Sinzinger H; Ring F; Pinggera WF Klin Wochenschr; 1979 Oct; 57(20):1137-8. PubMed ID: 513606 [TBL] [Abstract][Full Text] [Related]
18. Failure of platelet markers to evaluate membrane biocompatibility during a combined hemodialysis-hemoperfusion treatment. Buccianti G; Giaretto S; Pogliani EM; Lorenz M; Valenti G; Bianchi ML; Cresseri D Artif Organs; 1987 Oct; 11(5):416-20. PubMed ID: 2961320 [TBL] [Abstract][Full Text] [Related]
19. Decreased platelet sensitivity to prostacyclin (epoprostenol) during hemodialysis. Kristensen SD; Knudsen F; Nielsen AH; Ring T Clin Nephrol; 1984 Apr; 21(4):230-4. PubMed ID: 6375926 [TBL] [Abstract][Full Text] [Related]
20. Effect of a single pentoxifylline administration on platelet sensitivity, plasma factor activity, plasma-6-oxo-PGF1 alpha and thromboxane B2 in healthy volunteers. Pohanka E; Sinzinger H Prostaglandins Leukot Med; 1986 May; 22(2):191-200. PubMed ID: 3523540 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]